Agios Pharmaceuticals, Inc. (AGIO) announced that the FDA has granted orphan drug designation to its novel pyruvate kinase (PK) activator, tebapivat, for the treatment of myelodysplastic syndromes (MDS), a rare type of blood cancer.The FDA generally grants orphan drug designation to investigational therapies that address rare medical diseases or conditions affecting fewer than 200,000 people in the United States. The perquisites that come from this designation include assistance in the drug development proc ...